FINWIRES · TerminalFinancial News · Live TerminalLIVE

HKG:1093

60 stories mentioning HKG:1093Updated just now

Every FINWIRES story that references HKG:1093, newest first.

What are analysts saying about HKG:1093?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on HKG:1093?

CSPC Pharma Unit's Marketing Application for Anti-Inflammatory Drug Accepted in China

CSPC Pharmaceutical Group's (HKG:1093) unit CSPC Megalith Biopharmaceutical's marketing authorization application for the Secukinumab Injection was accepted by China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The drug can help alleviate symptoms of diseases including psoriasis, psoriatic arthritis, and axial spondyloarthritis by reducing inflammation.

CSPC Pharma Unit's Marketing Application of Edaglutide Alpha Injection's New Indication Accepted in China

CSPC Pharmaceutical Group's (HKG:1093) unit CSPC Baike (Shandong) Biopharmaceutical's second marketing authorization application for Edaglutide Alpha Injection was accepted by China's National Medical Products Administration.The indication for this application is glycaemic control in adults with type 2 diabetes, according to a Thursday Hong Kong bourse filing.A marketing authorization application for the same drug for the indication of long-term weight management in obese adults was accepted by the regulator in October 2025.

CSPC Pharmaceutical Marketing Application for Hypertension Drug Accepted in China

CSPC Pharmaceutical Group's (HKG:1093) marketing application for Valsartan and Levamlodipine Maleate Tablets was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The indication for the application is the treatment of mild-to-moderate essential hypertension inadequately controlled by monotherapy.

CSPC Pharmaceutical's Paclitaxel Cancer Drug Wins Marketing Approval in China

CSPC Pharmaceutical Group (HKG:1093) said its quick-dissolving injectable version of chemotherapy drug paclitaxel obtained marketing approval in China, according to a Monday filing with the Hong Kong bourse.It is indicated for the treatment of metastatic breast cancer after failure of combination chemotherapy or breast cancer relapsewithin 6 months of adjuvant chemotherapy, the filing said.

Alphamab Says Phase 3 Study of Breast Cancer Drug Meets Primary Endpoint

Alphamab Oncology (HKG:9966) said a Phase 3 study of Anbenitamab, or KN026, which it co-developed with Shanghai JMT-Bio Technology, a subsidiary of CSPC Pharma (HKG:1093), met its primary endpoint in the first-line treatment of HER2-positive advanced breast cancer, according to a Wednesday bourse filing.The company said KN026, in combination with albumin-bound docetaxel HB1801, significantly improved progression-free survival and reduced the risk of disease progression or death compared with the current standard regimen of trastuzumab, pertuzumab, and docetaxel.The study enrolled about 880 patients and compared KN026 plus HB1801 against the standard treatment regimen in patients with HER2-positive advanced breast cancer.

HKG:1093HKG:9966

CSPC Pharmaceutical Gets Trial Nod for Obesity Drug from US FDA

CSPC Pharmaceutical Group (HKG:1093) obtained clinical trial approval for Semaglutide Long-acting Injection from the U.S. Food and Drug Administration (FDA), according to a Monday Hong Kong bourse filing.The indication for the approval is weight management in adults who are overweight or obese alongside a reduced-calorie diet and increased physical activity.

CSPC Pharmaceutical Drug Shows 'Favorable' Anti-tumor Profile in Study

CSPC Pharmaceutical Group (HKG:1093) said currently available clinical data for its drug candidate SYS6043 indicates it could become a treatment option for multiple tumor types, according to a Tuesday filing with the Hong Kong bourse.According to the company, the medicine demonstrated "favorable anti-tumor activity" in subjects enrolled in an open-label, phase 1/2 clinical study in China.Among the 533 evaluable patients, the objective response rate was 41.8% while the median duration of response stood at 6.9 months. The disease control rate among the patients was assessed at 81.4%.Based on the results, the firm said it would advance related studies of the drug in ovarian cancer, breast cancer, and small cell lung cancer.

CSPC Pharmaceutical Wins Chinese Regulatory Nod for SYS6063 Clinical Trial

CSPC Pharmaceutical Group (HKG:1093) received Chinese regulatory approval to begin clinical trials of SYS6063, a CAR-T cell injection, according to a Tuesday filing with the Hong Kong bourse.The indication for the approved clinical trial in China is systemic lupus erythematosus, a chronic autoimmune disease.

CSPC Pharmaceutical Receives $1.2 Billion Upfront Payment From AstraZeneca

CSPC Pharmaceutical (HKG:1093) received $1.2 billion as part of a collaboration and license agreement with AstraZeneca to develop innovative long-acting peptide medicines.The amount represents the upfront payment agreed by both parties when the experimental drugs for obesity and weight-related conditions-focused deal was announced earlier this year, according to a Hong Kong bourse filing on May 29.CSPC is eligible for up to $3.5 billion in development milestones and up to $13.8 billion in sales milestones, and double-digit royalties on net sales.

CSPC Pharma Unit Gets Marketing Nod for Gastroesophageal Junction Cancer Drug in China

CSPC Pharmaceutical (HKG:1093) unit Shanghai JMT-BIO Technology's Anbenitamab Injection obtained marketing authorization from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The drug was co-developed by the subsidiary and Jiangsu Alphamab Biopharmaceuticals.The approved indication is for use of the drug in combination with chemotherapy to treat gastric or gastroesophageal junction adenocarcinoma.

Research110d ago

UOB Kay Hian Downgrades CSPC Pharmaceutical Group to Sell from Hold; Price Target is HK$6

CSPC Pharmaceutical Group (HKG:1093) has an average rating of overweight and mean price target of HK$12.05, according to analysts polled by FactSet.

CSPC Pharmaceutical's Profit Falls 42% in Q1

CSPC Pharmaceutical (HKG:1093) posted profit attributable to shareholders of 859.8 million yuan for the first quarter, down 42% from 1.48 billion yuan a year earlier, according to a Wednesday Hong Kong bourse filing.Earnings per share at the drugmaker came in at 0.0754 yuan from 0.1291 yuan in the prior-year period.Quarterly revenue fell 7.8% to 6.47 billion yuan from 7.01 billion yuan a year earlier.Despite the profit contraction, the company boosted its R&D spending by 7.7% to 1.403 billion Yuan, dedicating 26.8% of finished drug revenue to advance more than 130 clinical projects and accelerate its pipeline transition.

CSPC Pharma Gets Registration Nod for Ulcer Drug in China

CSPC Pharmaceutical (HKG:1093) obtained drug registration approval for its Lansoprazole Enteric-coated Capsules from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The product is indicated to treat gastric ulcer, duodenal ulcer, reflux esophagitis, Zollinger-Ellison syndrome, and anastomotic ulcer.

CSPC Innovation Pharma Gets China Nod for Psoriasis Drug

CSPC Innovation Pharmaceutical (SHE:300765, HKG:1093) received drug registration from China's medical products administrator for ustekinumab injection.The drug, branded as Enyike, is used to treat moderate to severe plaque psoriasis, according to Friday filings with the Shenzhen and Hong Kong bourses.

HKG:1093SHE:300765

CSPC Pharma Gets Registration Nod for Renal Disease Drug in China

CSPC Pharmaceutical (HKG:1093) obtained drug registration approval for the budesonide enteric-coated capsules from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.The drug is indicated to treat adult patients with primary immunoglobulin A nephropathy at risk of disease progression to reduce the loss of renal function.

CSPC Pharma Secures China Approval for Advanced Cancer Drug Trial

CSPC Pharmaceutical (HKG:1093) received approval from China's National Medical Products Administration for clinical trials of its SYH2095 tablets for advanced malignant tumors, according to a Monday Hong Kong bourse filing.Shares of the drugmaker were down over 1% in Tuesday morning trade.The drug is a highly selective lysine acetyltransferase 6, or KAT6, inhibitor co-developed with Hangzhou Innogate Pharma, the filing said.

CSPC Pharmaceutical's Tumor Drug Gets Breakthrough Therapy Designation in China

CSPC Pharma's (HKG:1093) SYS6010 obtained breakthrough therapy designation from China's National Medical Products Administration, according to a Monday Hong Kong bourse filing.The proposed indication is for use as monotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma.

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

HKG:1093HKG:2453

CSPC Pharma Unit's Tumor Drug Reaches Primary Efficacy Endpoint

CSPC Pharmaceutical (HKG:1093) said the phase Ib/III clinical study of Sirolimus for Injection (Albumin-bound) met its pre-specified primary efficacy endpoint, showing statistically significant differences and clear clinical benefits, according to a Monday Hong Kong bourse filing.The drug was developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang), a unit of the company for the treatment of advanced malignant perivascular epithelioid cell tumour.

CSPC Pharmaceutical Gets China Nod for Clinical Trial of Tumor Drug

CSPC Pharmaceutical (HKG:1093) obtained clinical trial approval for SYS6051 from China's National Medical Products Administration, according to a Wednesday Hong Kong bourse filing.The indication for the approval is advanced solid tumors. Preclinical studies demonstrated good anti-tumor effects on a variety of cancers.

Showing 41-60 of 60

Track with the FINWIRES app suite

Track HKG:1093 in your portfolio

Analyze HKG:1093 options with the wheel strategy

See market sentiment on HKG:1093